期刊文献+

麦考酚钠肠溶片与吗替麦考酚酯胶囊联合质子泵抑制剂对肾移植患者酶酚酸暴露的影响 被引量:3

Effect of Myfortic and CellCept combined with proton pump inhibitor on mycophenolic acid in kidney transplantation patients
下载PDF
导出
摘要 背景:麦考酚钠肠溶片与经典的免疫抑制剂吗替麦考酚酯胶囊在体内吸收代谢场所有所不同,与相关药物的联合应用造成了二者在代谢水平的差异,从而可能导致临床疗效的差异。目的:探讨麦考酚钠肠溶片与吗替麦考酚酯胶囊联合质子泵抑制剂的临床应用对肾移植患者酶酚酸暴露的影响。方法:选取2010-05/2011-05于解放军第309医院全军器官移植中心应用麦考酚钠肠溶片患者17例和应用吗替麦考酚酯胶囊患者16例为研究对象,采用麦考酚钠肠溶片/吗替麦考酚酯胶囊+环孢素/他克莫司+类固醇激素的免疫抑制方案,麦考酚钠肠溶片540mg12h给药1次,吗替麦考酚酯胶囊750mg12h给药1次。结果与结论:麦考酚钠肠溶片组和吗替麦考酚酯胶囊组患者肾移植后肾功能均恢复正常。麦考酚钠肠溶片组酶酚酸平均达峰时间、平均达峰浓度、平均半衰期和均平均药-时曲线下面积高于吗替麦考酚酯胶囊组(P<0.05),说明麦考酚钠肠溶片临床联合应用质子泵抑制剂对肾移植患者酶酚酸暴露的治疗效果优于吗替麦考酚酯胶囊。 BACKGROUND: The absorption and metabolism places in vivo of Myfortic are different with classic immunosuppressant CellCept, this is due to the combination with related drugs and results in the different clinical effects. OBJECTIVE: To explore the effect of Myfortic and CellCept combined with proton pump inhibitor (PPI) on mycophenolic acid in kidney transplantation patients. METHODS: Seventeen patients with Myfortic and 16 patients with CellCept who were treated in the 309 Hospital of Chinese PLA as study group during May 2010 to May 2011. Myfortic/CellCept+ciclosporin/Tacrolimus+steroid hormone was regarded as the immunosuppressive regimen, 540 mg Myfortic and 750 mg CellCept was injected once every 12 hours. RESULTS AND CONCLUSION: The kidney function of the patients was recovered to normal in Myfortic and CellCept groups. The average peak time, peak concentration, half life period and the area under the curve of the mycophenolic acid in Myfortic group were higher than those in the CellCept group (P 〈 0.05). It indicates that the therapeutic efficacy of Myfortic combined with PPI on mycophenolic acid in kidney transplantation patients is better than that of CellCept.
机构地区 解放军第
出处 《中国组织工程研究与临床康复》 CAS CSCD 北大核心 2011年第53期9901-9904,共4页 Journal of Clinical Rehabilitative Tissue Engineering Research
  • 相关文献

参考文献23

  • 1Kelly P,Kahan BD.Review:metabolism of immunosuppressant drugs.Curr Drug Metab.2002;3(3):275-287.
  • 2李永翔,谭建明,范煜,沈兵,陈向锋,陈晓波,孙星.免疫抑制剂致肾移植患者十二指肠溃疡穿孔(附1例报告并文献复习)[J].临床泌尿外科杂志,2005,20(10):595-596. 被引量:4
  • 3Sarkio S,Halme L,Kyll?nen L,et al.Severe gastrointestinal complications after1,515adult kidney transplantations.Transpl Int.2004;17(9):505-510.
  • 4Behrend M.Adverse gastrointestinal effects of mycophenolate mofetil:aetiology,incidence and management.Drug Saf.2001;24(9):645-663.
  • 5Mourad M,Malaise J,Chaib Eddour D,et al.Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.Clin Chem.2001;47(1):88-94.
  • 6Knoll GA,MacDonald I,Khan A,et al.Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation.J Am Soc Nephrol.2003;14(9):2381-2386.
  • 7Pelletier RP,Akin B,Henry ML,et al.The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation.Clin Transplant.2003;17(3):200-205.
  • 8Díaz B,González Vilchez F,Almenar L,et al.Gastrointestinal complications in heart transplant patients:MITOS study.Transplant Proc.2007;39(7):2397-2400.
  • 9郭峰松,丘永平,余新跃.慢性肾功能衰竭尿毒症326例临床分析[J].中国医疗前沿,2011,6(5):45-45. 被引量:8
  • 10Miura M,Kagaya H,Satoh S,et al.Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.Ther Drug Monit.2008;30(5):559-564.

二级参考文献10

共引文献11

同被引文献32

  • 1刘秋菊,姜玉珍,贾姣源.化疗后骨髓抑制危险因素分析[J].江西医学院学报,2005,45(3):48-50. 被引量:20
  • 2李戈.骨髓抑制防治概况[J].中医药学刊,2006,24(5):888-890. 被引量:16
  • 3谭志荣,欧阳冬生,郭栋,陈尧,韩春婷,曾玲,郑姣,周淦,王连生,李智,刘昭前,胡东莉,刘英姿,王丹,周宏灏.简单灵敏的高效液相色谱法测定人血浆中吗替麦考酚酸的浓度[J].药物分析杂志,2006,26(10):1437-1440. 被引量:3
  • 4Mok CC. Understanding lupus nephritis: diagnosis, man- agement, and treatment options[J]. Int .l Womens Health, 2012,4 : 213.
  • 5Appel GB. New and future therapies for lupus nephritis[J]. Cleve Clin JMed, 2012,79(2) : 134.
  • 6de Winter BC, van Gelder T, Sombogaard F, et al. Phar- macokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipi- ents[J]. JPharmacokinet Pharmacodyn, 2009,36(6) : 541.
  • 7Budde K, Glander P, Kramer BK, et al. Conversion from myeophenolate mofetil to enteric-coated mycophenolate sodium inmaintenanee renal transplant recipients receiving tacrolimus: clinical, pharmaeokinetic, and pharmacodynamie outcomes [-J. Transplantation, 2007, 83(4):417-426.
  • 8Mukhopadhyay P, Sinha U, Banerjee J, et al. The effects in correction of anaemia in chronic kidney disease with erythropoietin therapy-preference to cardiovascular, neurologic and general well-being of patients from a tertiary care centre [-J. Indian Med Assoc, 2012, 110(12):885-888.
  • 9SobiakJ, Kamifiska J, Glyda M,' et al. Effect of mycophenolate mofetil on hematological side effects incidence in renal transplant recipients[-J. Clin Transplant, 2013, 27 (4) :407-414.
  • 10yon VietinghoffS, Ouyang H, Ley K. Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 production[J]. Kidney Int, 2010, 78(1):79-88.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部